Portfolio Company News

ZS Pharma Presents New Data from ZS003 a Two Week Phase 3 Trial Demonstrating that ZS-9 Prevented Recurrence of Hyperkalemia in Heart Failure Patients on RAASi

Data Featured as Oral Presentation During a Late-Breaking Clinical Trial Session at the Heart Failure Society of America (HFSA) 18th Annual Scientific Meeting

 Coppell, Texas – September 15, 2014 - ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced results of a secondary analysis of ZS003, a two week pivotal Phase 3 trial of ZS-9 (sodium zirconium cyclosilicate), (more…)

Ear biotech Otonomy sets terms for $80 million IPO

Source:  IPO investment firm Renaissance Capital

Otonomy, a late-stage biotech developing sustained-exposure treatments for ear diseases, announced terms for its IPO on Friday. The San Diego, CA-based company plans to raise $80 million by offering 5.3 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Otonomy would command a fully diluted market value of $315 million. (more…)

Tryton Medical Enrolls First Patient in the EXTENDED Access Registry A Single Arm Study Designed to Support FDA Submission for US Approval

Durham, N.C. – July 28, 2014Tryton Medical, Inc., the leading developer of stents to treat bifurcation lesions, announced that the first patient has been enrolled in the EXTENDED Access Registry (Tryton IDE XA registry), a single arm study of its Tryton Side Branch Stent. The Tryton IDE XA registry is designed to support FDA submission for US approval and is expected to enroll 133 patients from Europe and the United States. Indulis Kumsars, M.D. of P. Stradins University Hospital, Latvian Centre of Cardiology enrolled the first patient. (more…)

ZS Pharma Completes Patient Enrollment in ZS004, Its Second Phase 3 Study of ZS-9 in Patients with Hyperkalemia

Company expects to announce top-line results late Q3 or early Q4 2014

Coppell, Texas – July 14, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced today that it has completed enrollment in ZS004, its second Phase 3 clinical trial of ZS-9 (sodium zirconium cyclosilicate), (more…)

Otonomy Files Registration Statement for Proposed Initial Public Offering

SAN DIEGO, July 14, 2014 /PRNewswire/ – Otonomy, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. (more…)

ZS Pharma Announces Allowance of Two U.S. Patent Applications for ZS-9

Applications cover composition of matter and methods of treating hyperkalemia and carry a patent term to at least 2032

Coppell, Texas – July 8, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced today that it has received Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Numbers 13/371,080 and 14/036,489 for ZS-9 (sodium zirconium cyclosilicate), the Company’s product candidate in Phase 3 development for the treatment of hyperkalemia. (more…)

ZS Pharma Announces Start of Enrollment of Phase 3 Long-Term Maintenance Study of ZS-9 in Patients with Hyperkalemia

–Open-Label Safety Study Evaluating Long-Term Safety and Efficacy of Oral Investigational Hyperkalemia Treatment—

Coppell, Texas – June 26, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that it has begun enrolling patients in ZS005, a Phase 3 open-label, 12-month, long-term maintenance study of ZS-9, an investigational treatment for hyperkalemia. (more…)

ZS Pharma Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Over-Allotment Option

Coppell, Texas – June 23, 2014 – ZS Pharma, Inc., a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced the closing of its initial public offering of 6,836,111 shares of common stock at a public offering price of $18.00 per share. (more…)

ZS Pharma, Inc. Announces Pricing of Initial Public Offering

COPPELL, Texas–(BUSINESS WIRE)– ZS Pharma, Inc., a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced the pricing of its initial public offering of 5,944,444 shares of its common stock at a price to the public of $18.00 per share. (more…)

ZS Pharma to Present Data from Phase 3 Trial of ZS-9 in Late-Breaking Poster Presentation at the American Diabetes Association (ADA) Scientific Sessions

Coppell, Texas – June 13, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that data from a pivotal Phase 3 trial of ZS-9, its investigational treatment for hyperkalemia, will be presented as a late-breaking clinical trial poster during the 74th American Diabetes Association (ADA) Scientific Sessions being held in San Francisco from June 13 to 17, 2014.

(more…)

slot machine gratis . disc profile . proofreading . Best Invisible Fence . Rechtsschutzversicherung